Polsinelli, a well-renowned law firm, has bolstered its Hatch-Waxman & Biologics practice by bringing Chad Landmon on board as a shareholder and chair. Landmon, who joins the firm in Washington, comes with a robust track record. He has extensive experience in navigating the complex landscape of pharmaceutical and biologics patent litigation as well as overcoming regulatory hurdles posed by the Food and Drug Administration (FDA). His client portfolio includes leading manufacturers of pharmaceuticals, biologics, medical devices, and human tissue products with revenues exceeding billions of dollars annually.
Over the past decade, Landmon has litigated more than 60 cases, indicating a high degree of proficiency and expertise that will likely benefit Polsinelli and its clientele. This strategic move is anticipated to further strengthen the firm’s capabilities in the highly specialized field of Hatch-Waxman and biologics law. More details about Chad Landmon’s appointment can be found in Polsinelli’s official announcement.
For additional coverage on this development, visit Bloomberg Law here.